The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Safety of the long-term use of proton pump inhibitors
Open accessAbstract
The proton pump inhibitors (PPIs) as a class are remarkably safe and effective for persons with peptic ulcer disorders. Serious adverse events are extremely rare for PPIs, with case reports of interstitial nephritis with omeprazole, hepatitis with omeprazole and lansoprazole, and disputed visual disturbances with pantoprazole and omeprazole. PPI use is associated with the development of fundic gland polyps (FGP); stopping PPIs is associated with regression of FGP. In the absence of Helicobacter pylori infection, the long-term use of PPIs has not been convincingly proven to cause or be associated with the progression of pre-existing chronic gastritis or gastric atrophy or intestinal metaplasia. Mild/modest hypergastrinemia is a physiological response to the reduction in gastric acid secretion due to any cause. The long-term use of PPIs has not been convincingly proven to cause enterochromaffin-like cell hyperplasia or carcinoid tumors. PPIs increase the risk of community acquired pneumonia, but not of hospital acquired (nosocomial) pneumonia. There is no data to support particular care in prescribing PPI therapy due to concerns about risk of hip fracture with the long-term use of PPIs. Long-term use of PPIs does not lead to vitamin B12 deficiencies, except possibly in the elderly, or in persons with Zollinger-Ellison Syndrome who are on high doses of PPI for prolonged periods of time. There is no convincingly proven data that PPIs increase the risk of Clostridium difficile-associated diarrhea in persons in the community. The discontinuation of PPIs may result in rebound symptoms requiring further and even continuous PPI use for suppression of symptoms. As with all medications, the key is to use PPIs only when clearly indicated, and to reassess continued use so that long-term therapy is used judiciously. Thus, in summary, the PPIs are a safe class of medications to use long-term in persons in whom there is a clear need for the maintenance of extensive acid inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Malfertheiner, P., Megraud, F., O'Morain, C., Bazzoli, F., El-Omar, E., Graham, D., Hunt, R., Rokkas, T., Vakil, N., Kuipers, E. J., et al. (2007) · Gut · doi:10.1136/gut.2006.101634 · Cited by 2,240
Total enteroscopy with a nonsurgical steerable double-balloon method
Yamamoto, H., Sekine, Y., Sato, Y., Higashizawa, T., Miyata, T., Iino, S., Ido, K., & Sugano, K. (2001) · Gastrointestinal Endoscopy · doi:10.1067/mge.2001.112181 · Cited by 1,289
Pepin, J., Saheb, N., Coulombe, M.-A., Alary, M.-E., Corriveau, M.-P., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/496986 · Cited by 995
Risk of Community-Acquired Pneumonia and Use of Gastric Acid–Suppressive Drugs
Laheij, R. J. F. (2004) · JAMA · doi:10.1001/jama.292.16.1955 · Cited by 877
The Medical Review Article: State of the Science
MULROW, C. D. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-3-485 · Cited by 856
Long-term sequelae of Helicobacter pylori gastritis
Kuipers, E. J., Peña, A. S., Festen, H. P. M., Meuwissen, S. G. M., Uyterlinde, A. M., Roosendaal, R., Pals, G., & Nelis, G. F. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91084-0 · Cited by 769
Kuipers, E. J., Lundell, L., Klinkenberg-Knol, E. C., Havu, N., Festen, H. P. M., Liedman, B., Lamers, C. B. H. W., Jansen, J. B. M. J., Dalenbäck, J., Snel, P., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604183341603 · Cited by 769
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
Juurlink, D. N., Gomes, T., Ko, D. T., Szmitko, P. E., Austin, P. C., Tu, J. V., Henry, D. A., Kopp, A., & Mamdani, M. M. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.082001 · Cited by 766
Systematic review of the risk of enteric infection in patients taking acid suppression
Leonard, J., Marshall, J. K., & Moayyedi, P. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01275.x · Cited by 633
Cited by
Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis
Janarthanan, S., Ditah, I., Adler, D. G., & Ehrinpreis, M. N. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.179 · Cited by 538
for the SIF-AIGO-FIMMG Group, Scarpignato, C., on behalf of the Italian Society of Pharmacology, T. I. A. O. H. G., Gatta, L., Zullo, A., & Blandizzi, C. (2016) · BMC Medicine · doi:10.1186/s12916-016-0718-z · Cited by 469
Ito, T., & Jensen, R. T. (2010) · Current Gastroenterology Reports · doi:10.1007/s11894-010-0141-0 · Cited by 309
Thomson, M., Tringali, A., Dumonceau, J., Tavares, M., Tabbers, M. M., Furlano, R., Spaander, M., Hassan, C., Tzvinikos, C., Ijsselstijn, H., et al. (2017) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001408 · Cited by 290
Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions
Song, H., Zhu, J., & Lu, D. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010623.pub2 · Cited by 132
Metadata
- Authors
- Thomson, A. B.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2010
- Volume
- 16
- Issue
- 19
- Pages
- 2323
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W2138543113
- Cited by
- 315
- References
- 119
- FWCI
- 29.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of the long-term use of proton pump inhibitors. https://app.cochat.ai/papers/10.3748/wjg.v16.i19.2323
- The paper
- Thomson, A. B. (2010). Safety of the long-term use of proton pump inhibitors. World Journal of Gastroenterology. https://doi.org/10.3748/wjg.v16.i19.2323
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.